Victoria Plamadeala1, Joseph L Kelley2, John K Chan3, Thomas C Krivak4, Michael J Gabrin1, Stacey L Brower5, Matthew A Powell6, Thomas J Rutherford7, Robert L Coleman8. 1. Helomics™ Corporation, Pittsburgh, PA, United States. 2. Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States. 3. Palo Alto Medical Foundation/Research Institute, Sutter Cancer Research Consortium, San Francisco, CA, United States. 4. The Western Pennsylvania Hospital, Pittsburgh, PA, United States. 5. Helomics™ Corporation, Pittsburgh, PA, United States. Electronic address: sbrower@helomics.com. 6. Washington University School of Medicine, St. Louis, MO, United States. 7. Yale University School of Medicine, New Haven, CT, United States. 8. University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Abstract
OBJECTIVE: Clinical validation of a chemoresponse assay was recently published, demonstrating a significant increase in overall survival in recurrent ovarian cancer patients treated with therapies to which their tumor was sensitive in the assay. The current study investigates the cost effectiveness of using the assay at the time of ovarian cancer recurrence from the payer's perspective. METHODS: Using a Markov state transition model, patient characteristics and survival data from the recent clinical study, the cumulative costs over the study horizon (71 months) for both the baseline (no assay) and intervention (assay consistent, hypothetical) cohorts were evaluated. RESULTS: The assay consistent cohort had an incremental cost effectiveness ratio (ICER) of $6206 per life year saved (LYS), as compared to the baseline cohort. Cost-effectiveness was further demonstrated in platinum-sensitive and platinum-resistant populations treated with assay-sensitive therapies, with ICERs of $2773 per LYS and $2736 per LYS, respectively. CONCLUSIONS: The use of a chemoresponse assay to inform treatment decisions in recurrent ovarian cancer patients has the potential to be cost-effective in both platinum-sensitive and platinum-resistant patients.
OBJECTIVE: Clinical validation of a chemoresponse assay was recently published, demonstrating a significant increase in overall survival in recurrent ovarian cancerpatients treated with therapies to which their tumor was sensitive in the assay. The current study investigates the cost effectiveness of using the assay at the time of ovarian cancer recurrence from the payer's perspective. METHODS: Using a Markov state transition model, patient characteristics and survival data from the recent clinical study, the cumulative costs over the study horizon (71 months) for both the baseline (no assay) and intervention (assay consistent, hypothetical) cohorts were evaluated. RESULTS: The assay consistent cohort had an incremental cost effectiveness ratio (ICER) of $6206 per life year saved (LYS), as compared to the baseline cohort. Cost-effectiveness was further demonstrated in platinum-sensitive and platinum-resistant populations treated with assay-sensitive therapies, with ICERs of $2773 per LYS and $2736 per LYS, respectively. CONCLUSIONS: The use of a chemoresponse assay to inform treatment decisions in recurrent ovarian cancerpatients has the potential to be cost-effective in both platinum-sensitive and platinum-resistant patients.
Authors: Candace M Howard; Nadim Bou Zgheib; Stephen Bush; Timothy DeEulis; Antonio Cortese; Antonio Mollo; Seth T Lirette; Krista Denning; Jagan Valluri; Pier Paolo Claudio Journal: Transl Oncol Date: 2020-08-28 Impact factor: 4.243